Connect with us

Hi, what are you looking for?

Culture

Setback for Sativex

Last week, UK-based GW Pharmaceuticals acknowledged that its cannabis-based oral spray, Sativex, failed a late-stage clinical trial as the experimental drug showed no evidence of reducing pain in cancer patients.

Participants in the initial Phase 3 trial were given Sativex, which is sprayed in the mouth, or a placebo three to 10 times a day for five weeks. However, test subjects receiving Sativex reported a statistically insignificant difference in pain relief from those receiving the placebo.

The disappointing trial results initially plunged GW stock around 13 percent on the morning of January 8, the first poor showing from the company since it listed on Nasdaq in 2013. But thanks to an encouraging update on GW’s cannabis-based childhood epilepsy drug Epidiolex, the company’s stock actually rebounded and closed up two percent.

The Phase 3 results are viewed by some as a blow against cannabis-based pharmaceutical products, as opposed to the entire plant in its pure, natural and medically effective form.

GW is scheduled to conduct further Phase 3 trials later this year and the company is hopeful that Sativex will eventually be approved for pain treatment in cancer patients. “Although we missed the primary endpoint in this trial, based upon the positive data seen in the Phase 2 program, we remain confident in the ability for Sativex to relieve cancer pain in this patient population,” GW chief executive Justin Gover said.

Sativex is currently approved for treating symptoms of multiple sclerosis.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

HT Newsletter

Subscribe for exclusive access to deals, free giveaways and more!

Thank you for subscribing.

Something went wrong.

Advertisement

You May Also Like

News

Could GW Pharmaceuticals see the same success with Sativex that they now have with Epidiolex?

Health

GW Pharmaceuticals has chosen the perfect moment to file its cannabis-derived therapy, Epidiolex, with U.S. regulators. The New England Journal of Medicine just published results from...

Culture

In June, the U.S. government lifted restrictions on scientific research into the medical and therapeutic benefits of marijuana, making biotech stocks hot property among...

CBD

The term CBD has been all over the media lately. Both Dr. Sanjay Gupta and the New York Times are talking about the helpful...

Do NOT follow this link or you will be banned from the site!